About this episode
The demand for Post-Trial Access (PTA) programs is rising rapidly — but how can organisations navigate the operational complexities and ethical considerations of ensuring continued access to investigational treatments?
This session explores current PTA trends, future expectations, and the real-world operational challenges companies face when planning for post-trial patient needs.
Whether you’re designing, managing or evaluating access strategies, this is a valuable opportunity to gain practical insights from those working on the front lines of implementation.
What we'll cover
- Key drivers behind the rise in PTA demand
- Practical steps to operationalise PTA at scale
- Common challenges and how to address them
- Future considerations: policy, patient needs and global consistency
Meet the speakers
Nicky Wisener
Vice President, Business Development, Clinigen
With over 20 years’ experience in the pharmaceutical industry, Nicky has held commercial roles at AstraZeneca and Servier before joining Clinigen over 13 years ago. She has deep expertise in Managed Access Programmes (MAPs), having worked in both business development and operational delivery. As VP of Business Development, she leads new business, strategy and consulting within the MAP function.
Dr Carole Kenyon
Senior Program Director, Clinigen
Carole joined Clinigen in 2018 and leads multiple Managed Access Programs on behalf of a Top 5 pharmaceutical client. With a PhD in Life Sciences and over a decade of program management experience in both clinical trials and access, she brings operational expertise and scientific insight. She is a Chartered Biologist and a member of the Royal Society of Biology.
Who should attend
- Market access and regulatory professionals
- Clinical operations and program directors
- Policy, ethics, and RWE teams
- Anyone involved in post-trial planning or implementation
Register to attend
Join us live or watch on demand after the event.
Regis